CSPC has a very strong financial position. As of 2022, its total debt outstanding is only 1.8% of its total cash in hand. Its annual capital expenditure for 2022 was CNY 1.8 billion. Given its CNY ...

CSPC has good financial health. As of 2021, it has almost no debt and over CNY 9 billion of cash on balance sheet, as well as consistently positive operating cash flow, so it is well-positioned to ...

CSPC Pharmaceutical Group (HK:1093) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now At 40% OFF!Make smarter investments with ...

CSPC Pharmaceutical Group’s breakthrough therapy, SYS6010, has been granted Breakthrough Therapy Designation in China for treating advanced non-small cell lung cancer with EGFR mutations.

CSPC Pharmaceutical Group ( ($HK:1093) ) has issued an announcement. CSPC Innovation Pharmaceutical Co., Ltd., a subsidiary of CSPC Pharmaceutical ...

CSPC Pharmaceutical Group’s subsidiary, CSPC Ouyi Pharmaceutical, has received acceptance for its marketing application of SYHX2011, a nano-formulation for advanced breast cancer treatment, from ...

CSPC Pharmaceutical Group has renewed lease agreements with CHL and NCP for three years starting January 2025, involving industrial premises in Shijiazhuang, China for drug production.

AI research is central to many of the deals. In April, French pharmaceutical giant Sanofi announced a $1.7 billion agreement ...

The CSPC Pharma vaccine was shown to have a protection effect of 70.2% seven to 28 days after injection, rising to 85.3% after 14 to 28 days.

Madrigal Pharmaceuticals has agreed to enter into a global license agreement with CSPC Pharmaceutical Group Limited for its preclinical oral small molecule glucagon-like-peptide-1 (GLP-1) receptor ...